Newsroom | 1307 results

Sorted by: Latest

COVID-19
-

ActivePure’s Advanced Photohydrolysis Technology Demonstrates Rapid Inactivation of SARS-CoV-2, RSV, and Monkeypox Virus in Aerosolized Form

DALLAS--(BUSINESS WIRE)--A new brief report published in the American Journal of Infection Control (AJIC) demonstrates that ActivePure’s Advanced Photohydrolysis (AP) Technology effectively and rapidly inactivates aerosolized SARS-CoV-2, respiratory syncytial virus (RSV), and monkeypox virus (MPXV). The study highlights AP’s potential as a valuable tool for improving indoor air quality and infection control, particularly in high-risk settings. About the Study: The study, which was designed and...
-

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion....
-

SINOVAC Announces Decision to Declare Cash Dividend

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company’s board of directors (the “Board”) has decided to declare a special cash dividend of US$55.00 per common share (the “Dividend”). The Board expects to fund the Dividend from available cash resources of the Company and its subsidiaries, including prior distributions from Sinovac Life Sciences Co., Ltd. and other oper...
-

SINOVAC Announces New Board Member and Chairman of the Audit Committee

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder an...
-

Preclinical Intranasal COVID-19 Vaccine Candidate Data Demonstrate Durable Immune Response and Broad Protection

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC today announced the recent publication of two preclinical studies in the Journal of Virology highlighting the durability of immune responses and broad protective efficacy of CVXGA, an intr...
-

Longhorn Vaccines and Diagnostics Honors World TB Day 2025, Underscoring a Commitment to Eradicating Tuberculosis with PrimeStore® MTM

BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today honors World Tuberculosis (TB) Day 2025 by reaffirming its commitment to ending TB globally through PrimeStore® MTM, the only FDA-cleared sample collection and transport device. PrimeStore enables safer, more accurate, and cost-effective TB sample collection and transport, thereby expanding acce...
-

Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral presentation at the Conference of Retroviruses and Opportunistic Infections (CROI) 2025, including new data from its global, double-blind, randomized, placebo-controlled Phase 3 study, Stopping COVID-19 pRogression with early Protease InhibitOr treatment – Post-Exposure Prophylaxis (SCORPIO-PEP) assess...
-

DOJ Asks Court to Dismiss FTC-Xlear Lawsuit

AMERICAN FORK, Utah--(BUSINESS WIRE)--DOJ ASKS COURT TO DISMISS FTC-XLEAR LAWSUIT; Calls into Question FTC’s Authority to Require Clinical Studies for Non-Pharmaceutical Health Products...
-

Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Leerink’s Global Healthcare Conference 2025 in Miami, on Wednesday, March 12, 2025, at 10:40 a.m. Eastern Time. Webcast link can be found under Inve...
-

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay...